【摘要】：目的以順鉑為主的非小細(xì)胞肺癌化療方案不斷更新,目前研究旨在尋求療效的放大及毒副作用的縮小。黃腐酚被證明有抗癌及保護(hù)正常細(xì)胞的作用。本實(shí)驗(yàn)主要探討黃腐酚的不同給藥方式對(duì)順鉑誘導(dǎo)人非小細(xì)胞肺癌細(xì)胞株H1650凋亡的影響。方法采用CCK-8法檢測(cè)黃腐酚、順鉑單用及先用低濃度黃腐酚干預(yù),后補(bǔ)入順鉑對(duì)H1650細(xì)胞增殖的影響;使用流式細(xì)胞術(shù)分別分析先用黃腐酚后用順鉑、先用順鉑再補(bǔ)入黃腐酚2種干預(yù)方式對(duì)H1650細(xì)胞凋亡率或存活率的影響。結(jié)果 CCK-8檢測(cè)結(jié)果顯示,2μmol/L黃腐酚干預(yù)H1650細(xì)胞48h后,繼續(xù)給予20、40和80μmol/L順鉑干預(yù)24h,抑制細(xì)胞增殖率分別為(13.16±1.06)%、(19.14±1.67)%和(28.17±2.79)%,均低于同濃度順鉑單純干預(yù)24h組的(18.96±3.02)%、(23.28±1.43)%和(39.79±3.44)%,P0.05。流式細(xì)胞術(shù)檢測(cè)結(jié)果顯示,10、20和40μmol/L順鉑干預(yù)細(xì)胞24h后,繼續(xù)給予7[(85.66±3.19)%、(74.62±2.98)%和(59.55±2.70)%]或14μmol/L[(82.04±2.88)%、(76.50±3.11)%和(61.76±3.01)%]黃腐酚干預(yù)24h,其細(xì)胞存活率明顯高于同濃度順鉑單純干預(yù)48h組的(72.60±2.69)%、(56.98±3.80)%和(44.15±2.01)%,P0.05。3μmol/L黃腐酚干預(yù)細(xì)胞24h,棄培養(yǎng)液,更換10、20和40μmol/L順鉑再干預(yù)24h,其細(xì)胞凋亡率分別為(29.79±3.78)%、(30.53±3.89)%和(39.48±4.98)%,明顯高于順鉑單純干預(yù)24h組的(17.21±3.01)%、(14.53±2.99)%和(18.88±4.20)%,P0.05。結(jié)論黃腐酚直接有效保護(hù)順鉑對(duì)H1650細(xì)胞的殺傷,但低濃度黃腐酚的前期干預(yù)間接提高了順鉑對(duì)H1650細(xì)胞的凋亡率。
[Abstract]:Objective the chemotherapy regimen of cisplatin-based non-small cell lung cancer (NSCLC) has been continuously updated. Xanthohumol has been shown to have anti-cancer and protective effects on normal cells. This study was designed to investigate the effects of different administration of xanthate on apoptosis of human non-small cell lung cancer cell line H1650 induced by cisplatin. Methods CCK-8 assay was used to detect the effects of xanthohumol, cisplatin alone and low concentration xanthate on the proliferation of H1650 cells, and flow cytometry was used to analyze the proliferation of H1650 cells. Effects of cisplatin and xanthate on apoptosis and survival of H1650 cells. Results the results of CCK-8 assay showed that the inhibition rate of proliferation of H1650 cells was (13.16 鹵1.06)%, (19.14 鹵1.67)% and (28.17 鹵2.79)%, respectively, which was significantly lower than that of the control group (18.96 鹵3.02)%, (23.28 鹵1.43)% and (39.79 鹵3.44)%, respectively, after 48 hours of treatment with 2 渭 mol/L xanthohumol and 80 渭 mol/L cisplatin for 24 h, respectively, P 0.055.The results showed that the inhibition rate was (18.96 鹵3.02)%, (23.28 鹵1.43)% and (39.79 鹵3.44)%, respectively. The results of flow cytometry showed that 10 渭 mol/L and 40 渭 mol/L cisplatin treated the cells for 24 h. After continuous administration of 7 [(85.66 鹵3.19)%, (74.62 鹵2.98)% and (59.55 鹵2.70)%] or 14 渭 mol/L [(82.04 鹵2.88)%, (76.50 鹵3.11)% and (61.76 鹵3.01)%] xanthate for 24 h, the cell survival rate was significantly higher than that in the 48 h group treated with cisplatin alone (72.60 鹵2.69)%, (56.98 鹵3.80)% and (44.15 鹵2.01)%, P0.05.3 渭 mol/L xanthol for 24 h. The cell apoptosis rates were (29.79 鹵3.78)%, (30.53 鹵3.89)% and (39.48 鹵4.98)% in 10 渭 mol/L and 40 渭 mol/L cisplatin replacement group for 24 h, respectively, which were significantly higher than those in cisplatin alone group (17.21 鹵3.01)%, (14.53 鹵2.99)% and (18.88 鹵4.20)%, P0.05%. Conclusion xanthate can directly protect H1650 cells against cisplatin, but the early intervention of low concentration xanthohumol can indirectly increase the apoptosis rate of Cisplatin on H1650 cells.
【作者單位】： 武威職業(yè)學(xué)院直屬附屬醫(yī)院老年病科;甘肅省醫(yī)學(xué)科學(xué)研究院·甘肅省腫瘤醫(yī)院轉(zhuǎn)化醫(yī)學(xué)研究中心;長(zhǎng)春工業(yè)大學(xué)化學(xué)與生命科學(xué)學(xué)院;
【基金】：甘肅省中醫(yī)藥管理局科研課題(GKZ-2015-9)
【分類(lèi)號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 韓瑞麗;王小麗;鐘殿勝;趙娟;陳哲;孫琳琳;王競(jìng);張金棒;;表皮生長(zhǎng)因子受體突變細(xì)胞系H1650耐藥機(jī)制探討[J];中國(guó)肺癌雜志;2012年12期

，

本文編號(hào)：2278867